New results from a multicenter clinical trial show that combining immunotherapy drugs nivolumab and ipilimumab significantly improves treatment response in patients with advanced and difficult-to-treat cancers. The trial results have been pre-published in JAMA Oncology, accompanied by a commentary emphasizing the significance of the findings.